Last reviewed · How we verify
MPFF
At a glance
| Generic name | MPFF |
|---|---|
| Sponsor | Pierre Fabre Medicament |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients (PHASE3)
- Venoactive Drug Treatment of Pelvic Venous Disorders (PHASE3)
- The Efficacy of Aescin in Combination With Micronized Purified Flavonoid Fraction (MPFF) in the Control of Bleeding and Prevent Recurrence of Acute Internal Hemorrhoids, A Randomized Controlled Trial, A Pilot Study (EARLY_PHASE1)
- The Efficacy of Aescin in Combination With MPFF in the Early Control of Bleeding From Acute Internal Hemorrhoids, A Randomized Controlled Trial (NA)
- The MUFFIN-PTS Trial (PHASE3)
- Evaluation of The Effect of Loratadine Versus Diosmin/Hesperidin Combination on Vinca Alkaloids Induced Neuropathy (PHASE3)
- MIcronized Flavonoid Fraction After MechanO-Chemical Ablation
- Micronized Purified Flavonoid- Fraction (MPFF) in the Management of Radiation Proctitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MPFF CI brief — competitive landscape report
- MPFF updates RSS · CI watch RSS
- Pierre Fabre Medicament portfolio CI